Navigation Links
Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
Date:5/15/2008

.0 million of debt incurred during October 2007.

As of March 31, 2008, Pharmasset had approximately $63.0 million of cash and cash equivalents and approximately $1.2 million of short-term investments.

"R7128 for the treatment of hepatitis C virus (HCV) continues to demonstrate best-in-class potential based on its safety, efficacy and high barrier to resistance as demonstrated in 4-week Phase 1 clinical trials," stated Schaefer Price, Pharmasset's Chief Executive Officer. "We look forward to continuing the advancement and broadening the scope of this program by exploring additional Phase 1 cohorts, including an R7128 1000mg dose in patients with HCV genotype 1 and an R7128 1500mg dose in patients with HCV genotypes 2 and 3 who have not responded to prior therapy. We and Roche are currently focused on planning a global 12-week Phase 2b combination study of R7128 with Pegasys plus Copegus."

Highlights of the Quarter Ended March 31, 2008

-- Announced preliminary safety and efficacy results of two cohorts (500mg

and 1500mg) in a 4-week combination study of R7128 with Pegasys plus

Copegus for the treatment of HCV.

-- Appointed Herbert J. Conrad as a member of our Board of Directors and

the Nominating and Corporate Governance Committee.

-- Advanced a new series of proprietary nucleoside analogs that have

demonstrated potent anti-HCV activity.

Anticipated Highlights

-- Initiating dosing and announcing preliminary results of Cohorts 3 and 4

in a 4-week combination study of R7128 with Pegasys plus Copegus for

the treatment of HCV in the third calendar quarter of 2008.

-- Completing HBV patient enrollment for clevudine Phase 3 registration

studies in the second calendar half of 2008.

-- Initiating trial activities for a global 12-week Phase 2b combination

study of R7128 with Pegasys plus Copegus in the fourth calendar quarter


'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
2. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
3. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
4. Pharmassets Underwriters Release Shares from Lock-Up
5. Nephros Reports 2008 First Quarter Financial Results
6. PreMD Reports First Quarter Results
7. Lifeway Foods Reports Record 1st Quarter 2008 Results
8. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
9. Tiens Biotech Group (USA) Reports First Quarter Results
10. Cardiogenesis Reports First Quarter 2008 Results
11. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015 Unfortunately, a majority of shoes sold ... providing comfort to the users throughout the year. Be it ... from the local market, the makers generally tend to put ... process, often overlook comfort and health. To counter this problem ... creative heads at Vay Technologies have come up with uGALE, ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 evigilo, a ... solutions, has showcased its new branding by launching a ... , "The new brand identity: the logo depicting a ... to green, the tagline – To Know. To Act. ... path evigilo is charting. A global, borderless approach to ...
(Date:6/2/2015)... Allred Dental, a dental office based in San ... 2015 along with a $100 off with free oral sedation ... “Sometimes wisdom teeth can be impacted, meaning that they are ... only partially break through the gum, causing pain and inflammation ... young people, as they do not have fully developed wisdom ...
(Date:6/2/2015)... The JK-A0100EU secure smart card keyboard ... finance and healthcare. However, this keyboard can also be ... to enhance the security of their network. , The ... of a Smart Card before allowing access to the ... reader, the keyboard supports secure PIN entry. , The ...
(Date:6/2/2015)... Los Angeles, CA (PRWEB) June 02, 2015 ... "100K Factory" system was released to public yesterday, ... around the Internet. HonestyFirstReviews.com's senior product reviewer Tiffany ... posting a detailed review of the course on ... of training courses available for Internet marketers looking ...
Breaking Medicine News(10 mins):Health News:Vay Technologies Launches uGALE the High Tech Insole Technology for Shoes on KickStarter 2Health News:Vay Technologies Launches uGALE the High Tech Insole Technology for Shoes on KickStarter 3Health News:Keep calm! evigilos' "sun" will come out tomorrow – to know, to act, in time. 2Health News:$100 Off Coupon for Wisdom Teeth Extractions Offered at Allred Dental 2Health News:Introducing the New CHERRY JK-A0100EU Keyboard with Integrated Smart Card Reader for Access Control Security 2Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2
... , BRONX, N.Y., Aug. 3 Seven out of ... of bone and heart disease, according to a study by researchers at ... that vitamin D deficiency could place millions of children at risk for ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090803/DC55348 ) ...
... But another study finding suggests insulin treatment could boost ... Metformin, one of the most widely used diabetes drugs, ... odds for pancreatic cancer by 60 percent, a new ... Other common treatments, including the use of insulin or ...
... national study finds large jump in ER treatments since 1990 ... rise to the challenge of rock climbing for fun and ... increases, according to the first national study on the subject. ... rooms from 1990 to 2007 for fractures, sprains and other ...
... Dr. Laurence ... top sleep and dental sleep professionals at Somnomed,s first annual symposium in Hawaii August 4-6, ... (Vocus) August 1, ... joining dental sleep medicine,s top sleep and dental sleep professionals at Somnomed,s first annual ...
... untreated non-small cell lung cancer (NSCLC) patients over the ... bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported ... for the Study of Lung Cancer. "Based on ... tolerated and efficacious, though we,ll have to wait and ...
... Webcast: , , , What: ... August 6, 2009 @ 9:00AM CST , , Where: ... How: Live over the Internet -- ... Contact: Mark Kimbrough, Investor Relations at HCA Healthcare, +1-615 344 ...
Cached Medicine News:Health News:Millions Of U.S. Children Low In Vitamin D 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 3Health News:Rock-Climbing Injury Rate Soaring 2Health News:Laurence I. Barsh, DMD, Founder of Snoring Isn't Sexy, to speak at Somnomed's First Annual Symposium 2Health News:Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients 2
(Date:6/2/2015)... 2015 Kewaunee Scientific Corporation (Nasdaq: KEQU ... quarterly cash dividend of twelve cents per outstanding share, ... at the close of business on June 12, 2015. ... in 1906, Kewaunee Scientific Corporation is a recognized global ... healthcare, and technical furniture products. Products include steel, wood, ...
(Date:6/2/2015)... June 2, 2015   PDI , a ... announced a series of corporate commitments designed to ... reduce the threat of antimicrobial-resistant microorganisms as part ... for Disease Control and Prevention (CDC) and in ... Combat Antibiotic-Resistant Bacteria. Along with other ...
(Date:6/2/2015)... , June 02, 2015 Research and ... of the "Laboratory Centrifuges - Global Strategic ... Annual estimates and forecasts are provided for ... historic analysis is provided for these markets. Market ... secondary research. Company profiles are primarily based on ...
Breaking Medicine Technology:PDI Partners with White House and Centers for Disease Control and Prevention (CDC) to Combat Antimicrobial Resistance 2Laboratory Centrifuges - Global Strategic Business Report 2014-2020: Developed Markets Slowdown, While Emerging Markets Surge 2
... Cargille Immersion Oils are the standard - the ... against. Cargille Laboratories has consistently led in the ... 42 years. Here is the record: , When ... the classification of In Vitro Diagnostics in the ...
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
The ToxCup Drug Screen Cup is a one-step test for the rapid detection of up to five drugs of abuse and four adulteration tests. It's design integrates sample collection, drug/adulteration testing and...
Lasts up to 3 months , Absorbable copolymer of glycolic acid and trimethylene carbonate , Designed to provide relief from short term dry eye conditions. , Appropriate for surgery-related d...
Medicine Products: